Skip to main content

 

Main menu

  • Home
  • Articles
    • Current Issue
    • Archive
    • Editorials
    • Immunology Education
    • Most Read
    • On The Horizon Collection
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Services
    • Email Alerts
    • RSS Feeds
  • More
    • AAI Disclaimer
    • Feedback
  • Other Publications
    • American Association of Immunologists
    • The Journal of Immunology

User menu

  • Log in

Search

  • Advanced search
ImmunoHorizons
  • Other Publications
    • American Association of Immunologists
    • The Journal of Immunology
  • Log in
ImmunoHorizons

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Archive
    • Editorials
    • Immunology Education
    • Most Read
    • On The Horizon Collection
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Services
    • Email Alerts
    • RSS Feeds
  • More
    • AAI Disclaimer
    • Feedback
  • Follow ImmunoHorizons on Twitter
  • Follow ImmunoHorizons on RSS
Open Access

Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model

Naoko Iwata-Yoshikawa, Noriyo Nagata, Hiromi Takaki, Misako Matsumoto, Tadaki Suzuki, Hideki Hasegawa and Tsukasa Seya
ImmunoHorizons April 1, 2022, 6 (4) 275-282; DOI: https://doi.org/10.4049/immunohorizons.2200020
Naoko Iwata-Yoshikawa
*Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriyo Nagata
*Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiromi Takaki
†Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Misako Matsumoto
†Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;
‡Nebuta Research Institute for Life Sciences, Aomori University, Aomori, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Misako Matsumoto
Tadaki Suzuki
*Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Hasegawa
*Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan;
§Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsukasa Seya
†Department of Vaccine Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;
‡Nebuta Research Institute for Life Sciences, Aomori University, Aomori, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tsukasa Seya
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    The experimental protocol of this study.

    Numbers of mice in each group are shown in the inset table. Small-scale preliminary experiments were performed to determine the conditions of this study.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    ARNAX adjuvant shows some advantages compared with Alum in vaccination.

    Adjuvant efficacy and lung histopathology in mice immunized with recombinant S protein with ARNAX120. Female BALB/c mice were vaccinated with each set of Ag/adjuvant. Mice immunized with 0.1 μg S protein with or without adjuvant were challenged with 106 TCID50 of mouse-adapted SARS‐CoV (n = 6–10). (A) Serum neutralizing Ab titers after the second immunization. The line indicates the limit of detection (<4). *p < 0.05; ***p < 0.001, via Dunn's multiple comparisons test following the Kruskal–Wallis test. (B) Body weight changes after SARS-CoV challenge infection. (C) Survival curves after SARS‐CoV challenge infection. Comparisons of survival with respect to the control group were performed using the log-rank test followed by Kaplan–Meier survival analysis. (D) Virus titers in lungs on day 3 postchallenge. **p < 0.01, via Dunn's multiple comparisons test following the Kruskal–Wallis test. (E) Lung histopathological findings on day 10 postchallenge. Upper panels, low magnification (scale bars, 200 µm); middle panels, high magnification (scale bars, 100 µm); lower panels, high magnification of the lung histopathological findings from the mice with the eosinophil infiltration were detected via eosinophil staining using C.E.M. Stain Kit (scale bars, 20 µm). The red arrows indicate representative eosinophils, and the blue arrows indicate plasma cells. Results of the PBS pretreated controls on day 5 postchallenge. Each image represents many fields from a specimen of an individual animal. (F) Number of eosinophils per lung section (n = 3–6) on day 10 postchallenge. Five 147,000-μm2 regions around the pulmonary bronchiole of each mouse were counted.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Histopathology of alveolar area of the lung in mice treated with Ag + adjuvant.

    (A) The alveolar regions in the lung specimens (Fig. 2) were enlarged. The different fields were shown with a high magnification under the microscope. Score of leukocyte infiltration was given in each panel as in Iwata-Yoshikawa et al. (14). (B) Representative images of alveoli with eosinophils (arrowheads or asterisks) from Ag + adjuvant-treated mice. Each image represents many fields from a specimen of an individual animal. The insets are higher-magnification images of the boxed area. H&E staining. Scale bars, 50 µm; 20 µm (insets).

PreviousNext
Back to top

In this issue

ImmunoHorizons: 6 (4)
ImmunoHorizons
Vol. 6, Issue 4
1 Apr 2022
  • Table of Contents
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about ImmunoHorizons.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model
(Your Name) has forwarded a page to you from ImmunoHorizons
(Your Name) thought you would like to see this page from the ImmunoHorizons web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model
Naoko Iwata-Yoshikawa, Noriyo Nagata, Hiromi Takaki, Misako Matsumoto, Tadaki Suzuki, Hideki Hasegawa, Tsukasa Seya
ImmunoHorizons April 1, 2022, 6 (4) 275-282; DOI: 10.4049/immunohorizons.2200020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model
Naoko Iwata-Yoshikawa, Noriyo Nagata, Hiromi Takaki, Misako Matsumoto, Tadaki Suzuki, Hideki Hasegawa, Tsukasa Seya
ImmunoHorizons April 1, 2022, 6 (4) 275-282; DOI: 10.4049/immunohorizons.2200020
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Alboserpin, the Main Salivary Anticoagulant from the Disease Vector Aedes albopictus, Displays Anti–FXa-PAR Signaling In Vitro and In Vivo
  • RXRα Regulates the Development of Resident Tissue Macrophages
  • Antigen and Immunogen: An Investigation into the Heterogeneity of Immunology Terminology in Learning Resources
Show more INNATE IMMUNITY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds

Copyright© 2022 by The American Association of Immunologists, Inc

Online ISSN 2573-7732